The Gerontological Society of America, founded in 1945, has spent eight decades working to promote the study of aging and to disseminate information about it to scientists, decision makers, and the general public. Its self-described role as the driving force behind advancing innovation in aging, both domestically and internationally, reflects an unusually broad mandate. Unlike single-discipline societies, the organization deliberately brings together biologists, physicians, psychologists, social scientists, social workers, and policy specialists, on the premise that aging is not a problem that any one field can solve alone. Its board of directors carries responsibility for stewarding that interdisciplinary mission, from scientific publishing and annual meetings to policy engagement in Washington.

Dr. Lipsitz arrives on the board with a career that mirrors the very interdisciplinarity the society champions. In addition to leading the Marcus Institute and serving as chief academic officer at Hebrew SeniorLife, he is a professor of medicine at Harvard Medical School and the former chief of the Division of Gerontology at Beth Israel Deaconess Medical Center. Since 2021, he has served as editor-in-chief of The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, one of the flagship publications in the field, where he oversees the peer-review process for research spanning the biology of aging and clinical geriatric medicine.

His own research program has focused on a set of problems that sit precisely at the intersection of biology and clinical care: age-related alterations in blood pressure regulation and cerebral blood flow, and how those alterations relate to falls, syncope, and cognitive dysfunction in older adults. The work is technically demanding because the systems involved are deeply interconnected. Blood pressure is not a fixed number but a dynamically regulated variable, controlled by reflexes that adjust heart rate, vascular tone, and blood volume from moment to moment. With advancing age, those reflexes can slow and become less precise, leaving older adults vulnerable to abrupt drops in pressure when they stand, a phenomenon known as orthostatic hypotension.

When blood pressure falls, the brain depends on a second line of defense: cerebral autoregulation, the capacity of blood vessels inside the brain to dilate or constrict in order to keep blood flow nearly constant across a range of pressures. Dr. Lipsitz’s research has examined how this autoregulatory capacity changes with age and disease, and how failures of regulation can transiently deprive the brain of adequate perfusion. Such episodes can manifest as syncope, the temporary loss of consciousness commonly known as fainting, or more subtly as lightheadedness, confusion, and cognitive dysfunction. Because these events are often recurrent and unpredictable, they carry consequences far beyond the episode itself.

Falls are among the most consequential outcomes of this chain of physiological events. In older adults, a fall can result in fractures, head injuries, hospitalization, loss of independence, and a cascade of declining health that is difficult to reverse. Understanding the hemodynamic mechanisms that precede falls, including drops in blood pressure on standing, abnormal responses to meals, and impaired cerebral blood flow regulation, offers a route to prevention that is grounded in mechanism rather than trial and error. That mechanistic orientation, linking measurements of vascular physiology to real-world outcomes such as fainting and falling, has been a hallmark of Dr. Lipsitz’s scholarly contribution and of the research culture at the institute he directs.

The Marcus Institute for Aging Research, part of Hebrew SeniorLife, is one of the country’s leading centers for research on aging, with a grant portfolio of 87 million dollars. Its scientists seek to transform the human experience of aging by conducting research aimed at ensuring a life of health, dignity, and productivity into advanced age. The institute carries out rigorous studies designed to discover the mechanisms of age-related disease and disability, to lead to the prevention, treatment, and cure of disease, to advance the standard of care for older people, and to inform public decision-making. Its location within a senior care organization gives researchers direct access to the clinical realities of aging, an advantage that helps keep laboratory questions tethered to the problems older adults and their families actually face.

Hebrew SeniorLife itself operates on a scale that makes it a significant platform for both care and research. The organization cares for more than 4,500 older adults each day across seven campuses throughout Greater Boston, offering services that range from in-home care, outpatient therapies, and an outpatient memory clinic to short- and long-term inpatient care, hospice, independent and assisted living, and affordable housing with services. It also trains future health care workers at the Lunder CareForce Institute and is affiliated with Harvard Medical School. This integration of care, housing, education, and research under one roof reflects a model in which findings from studies of aging can be translated into practice and tested in the daily lives of the people they are meant to serve.

The significance of the appointment extends beyond one institution. The United States, like much of the world, is experiencing a historic shift in the age structure of its population, and the scientific infrastructure devoted to aging, from journals and societies to research institutes and training programs, is being asked to respond. Boards of directors at scientific societies make consequential decisions about which research areas to elevate, how to support early-career scientists, how to communicate evidence to policymakers and the public, and how to ensure that the study of aging remains rigorous and inclusive across disciplines and countries. Leadership drawn from institutions that combine research with frontline care brings an operational understanding of how scientific knowledge does, and does not, reach the bedside.

For the Gerontological Society of America, the addition of Dr. Lipsitz to its board of directors reinforces the connection between the society’s interdisciplinary mission and the clinical science of aging. His dual perspective, as a physician-scientist who studies the physiology of blood pressure and cerebral blood flow and as an editor-in-chief responsible for the quality of published research in the field, positions him to contribute to the society’s work of promoting the study of aging and disseminating what it produces. As the organization continues its work as a driving force behind innovation in aging, the appointment signals a continued commitment to leadership grounded in decades of research on the mechanisms that determine whether the later years of life are lived with health, independence, and dignity.

Subject of Research: Appointment of geriatrician Lewis Lipsitz, MD, to the board of directors of the Gerontological Society of America

Article Title: Hebrew SeniorLife's Lewis Lipsitz, MD, named to board of directors of the Gerontological Society of America

Article References: Hebrew SeniorLife's Lewis Lipsitz, MD, named to board of directors of the Gerontological Society of America. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Gerontological Society of America, Lewis Lipsitz, Hebrew SeniorLife, Marcus Institute for Aging Research, aging research, gerontology, blood pressure regulation, cerebral blood flow, falls, syncope, cognitive dysfunction, Harvard Medical School

Gitelman syndrome is an autosomal recessive salt-losing tubulopathy first described in 1966. It arises from inactivating mutations in SLC12A3, the gene encoding the thiazide-sensitive sodium-chloride cotransporter known as NCC. This transporter sits exclusively on the apical membrane of epithelial cells lining the distal convoluted tubule, a short but critical segment of the nephron where sodium and chloride are reclaimed from the forming urine. When NCC fails, the kidney cannot properly conserve sodium, potassium, chloride, and magnesium. The biochemical signature is distinctive: hypokalemic metabolic alkalosis, low serum magnesium, unusually low urinary calcium, and appropriately elevated renin in a patient with normal or low blood pressure. With an estimated prevalence of roughly 1 to 10 per 40,000 people, it is among the more common inherited renal tubulopathies, yet its symptoms—muscle weakness, cramps, fatigue, salt craving, thirst—are so nonspecific that diagnosis is often delayed into adolescence or adulthood.

The patient’s history illustrates that delay vividly. As a child she suffered leg numbness while walking, night cramps, and bedwetting until about age twelve. She had fainted at least twice during emotional stress as a teenager, and her sister took potassium supplements for chronic hypokalemia. Her parents were first cousins, a clue pointing to a recessive condition. Despite these signals and decades of documented low potassium, no unifying diagnosis emerged until syncope began clustering dangerously. On admission her blood pressure was 97/62 mmHg with a heart rate of 60 beats per minute. Laboratory testing confirmed the classic tetrad: hypokalemic metabolic alkalosis with hypomagnesemia, hypocalciuria, and secondary hyperreninism. An electrocardiogram revealed sinus bradycardia, a prolonged QRS interval of 154 milliseconds with right bundle branch and left anterior fascicular blocks, and a QTc of 465 milliseconds with U waves—conduction abnormalities consistent with the electrical instability that potassium and magnesium depletion can produce.

The arrhythmia workup was thorough but largely unrevealing. Two weeks of continuous cardiac event telemetry during three fainting spells captured only sinus rhythm with occasional premature atrial and ventricular contractions—no sustained arrhythmias. Echocardiography, myocardial perfusion imaging, kidney and bladder ultrasound, electroencephalography, and advanced imaging of the head and neck were all normal. Tilt-table testing, however, showed distal sudomotor deficits and borderline heart rate and blood pressure responses during upright tilt, hinting at early autonomic neuropathy. The decisive clue came from the urine: ongoing potassium wasting paired with hypocalciuria. That combination prompted genetic testing, which identified a homozygous missense mutation in SLC12A3—c.2221G>A, p.Gly741Arg—confirming Gitelman syndrome. Notably, this variant was among the original mutations discovered when the genetic basis of the disease was first established in the 1990s, and it remains one of the most common pathogenic missense changes reported across cohorts, with a carrier allele frequency of about 0.04 percent in the gnomAD database.

Why does losing sodium upstream cause potassium wasting downstream? The pathophysiology is a cascade. Reduced NCC activity in the distal convoluted tubule means more sodium chloride reaches the collecting duct. There, the extra sodium drives electrogenic reabsorption through epithelial sodium channels, which depolarizes the tubular cells and creates a stronger electrical gradient favoring potassium secretion through ROMK and Maxi-K channels. The high tubular flow rate adds a mechanical stimulus, promoting flow-induced potassium secretion via BK channels and stimulating synthesis of prostaglandin E2, which further encourages potassium loss. Finally, the mild volume depletion characteristic of the disease activates the renin-angiotensin-aldosterone axis, and aldosterone amplifies distal potassium secretion even more. Interestingly, the authors note that potassium depletion itself can blunt aldosterone secretion independent of volume status, which may mask the expected hyperaldosteronism and complicate interpretation.

Treatment proved refractory at first. Even with a staggering total daily dose of 240 milliequivalents of potassium chloride plus magnesium oxide, sodium chloride, and the potassium-sparing diuretic amiloride, her serum potassium and magnesium remained stubbornly low. To help her return safely to work, clinicians escalated amiloride to 10 milligrams and added midodrine, a pressor agent, along with the nonsteroidal anti-inflammatory naproxen to raise blood pressure and reduce renal electrolyte excretion. The crucial innovation was monitoring: monthly spot urine and serum potassium measurements guided stepwise titration of amiloride up to 20 milligrams daily until urinary potassium wasting was suppressed, serum potassium improved, and the fainting stopped. When a major life event led her to stop all medications except potassium chloride about three months later, kaliuresis, hypokalemia, and syncope all returned—a natural experiment demonstrating that the multimodal regimen, not the supplements alone, was doing the heavy lifting.

The case is also a masterclass in interpreting spot urine electrolytes, which have no established universal reference ranges and must be read against the expected renal response for a given clinical context. Under dietary potassium restriction, urinary potassium excretion normally falls to 10 to 15 milliequivalents per day; excretion above 30 to 40 milliequivalents per day during hypokalemia is unmistakable evidence of renal wasting. A further wrinkle is urine concentration itself—dilute urine lowers measured potassium, concentrated urine raises it. Fortunately, this patient’s urine osmolality was remarkably consistent across visits, allowing straightforward comparison of serial values. The authors also flag a subtle complication: chronic hypokalemia can induce partial vasopressin resistance, an acquired urine-concentrating defect. Children with Gitelman syndrome have been shown to produce notably dilute urine after overnight water deprivation compared with unaffected peers, and while they concentrate better than patients with Bartter syndrome, these subtle water-handling impairments may be underrecognized and may exacerbate volume depletion.

Therapeutic options in Gitelman syndrome rest on limited evidence because the disease is rare. Standard care involves lifelong oral supplementation with sodium, potassium, chloride, and magnesium salts, with potassium-sparing diuretics, NSAIDs, and renin-angiotensin-aldosterone antagonists reserved for selected cases. NSAIDs curb renin secretion during hypovolemia; mineralocorticoid receptor antagonists and ENaC inhibitors counteract aldosterone-driven and flow-driven potassium secretion in the aldosterone-sensitive distal nephron. A randomized crossover study of 30 patients taking potassium and magnesium supplements found that indomethacin 75 milligrams, eplerenone 150 milligrams, and amiloride 20 milligrams each raised plasma potassium, with indomethacin most effective but most burdensome to the gut and kidneys. Diuretics also shrink extracellular fluid volume and can worsen orthostatic hypotension, although one small study found no obvious clinical impact. In this patient, sodium and naproxen titration was limited by palatability and dyspepsia, illustrating how real-world tolerability constrains theoretical regimens.

The authors argue that serial spot urine potassium measurements added something serum potassium alone could not. Hypokalemia in Gitelman syndrome is often treatment-resistant, and quantifying urinary losses tells the clinician how much oral repletion is needed to achieve a net positive balance. Spot samples are also far easier to obtain than 24-hour collections. When a potassium-sparing diuretic is working, urine potassium falls—and once kaliuresis is suppressed, pushing the diuretic higher adds little, whereas more potassium chloride becomes the rational lever. Suppressed kaliuresis also served as an objective marker of adherence. KCl alone, by contrast, would never have reduced urinary potassium excretion. The team acknowledges gaps: the field still lacks validated urine values and creatinine ratios that formally define potassium, sodium, and chloride wasting, and there was insufficient time on the effective regimen to test whether normal serum potassium could have been achieved with higher potassium chloride dosing.

The broader lesson reaches beyond this single patient. Syncope in Gitelman syndrome is mechanistically plausible but rarely documented; palpitations and arrhythmias occur in up to 60 percent of patients, and ventricular tachycardia or sudden cardiac death, while rare, remain feared complications. Whether this patient’s fainting stemmed from hypokalemia-induced conduction delays, volume depletion, impaired vasoconstriction, or early autonomic dysfunction cannot be fully disentangled, but severe hypokalemia with ongoing renal wasting justified aggressive correction regardless. The authors call for urine electrolytes to be integrated into routine practice for patients with blood pressure or electrolyte disorders, and for genetic testing of renal electrolyte transporter genes in patients with recurrent syncope and chronic electrolyte abnormalities. In an era of ever more sophisticated diagnostics, a simple spot urine sample, interpreted with physiological rigor, proved the thread that unraveled a decades-old mystery and, ultimately, kept a patient on her feet.

Subject of Research: Gitelman syndrome diagnosis and electrolyte-guided treatment of recurrent syncope

Article Title: Urine electrolytes guide treatment of Gitelman syndrome and recurrent syncope—A case report

Article References: Urine electrolytes guide treatment of Gitelman syndrome and recurrent syncope—A case report. (n.d.). https://doi.org/10.14814/phy2.71043

Image Credits: AI Generated

DOI: 10.14814/phy2.71043

Keywords: Gitelman syndrome, SLC12A3, hypokalemia, syncope, urine electrolytes, distal convoluted tubule, amiloride, renal tubulopathy, electrolyte disorders, cardiac arrhythmia, NCC cotransporter, case report